Could you give us a brief overview of the data you recently presented at the ESMO 2017 Congress (8–12th September, Madrid, Spain) exploring the efficacy and safety of ABP 980 compared with trastuzumab in patients with HER2 positive-early breast cancer?
What were the primary endpoints of this study?
What is the potential clinical significance of these findings?
Were there any significant differences in the safety profiles of ABP 980 and the originator product?
Would you like to find out more about biosimilars?
What do you think are the biggest challenges in the widespread adoption of biosimilars and how can we overcome these?
What do you think could be the timeframe for widespread adoption of biosimilars?
Do you have any closing comments?
Richard Markus is the Vice President for the Global Development at Amgen, Inc., where he leads research and development activities for the Biosimilar Business Unit. After joining Amgen as Clinical Development Medical Director and Medical Affairs Lead for denosumab, he served as the Global Development Leader for darbepoetin alfa in Oncology. Richard now oversees non-clinical and clinical activities across the portfolio for 10 molecules in multiple therapeutic areas and indications of use.
Richard received his BSc degree from the University of California, Los Angeles (CA, USA). He earned his MD/PhD from the University of Southern California (CA, USA) and stayed there to complete his medical training before going into industry to lead clinical research.’)